Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT(R) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
(NASDAQ:DRTS),(NASDAQ:DRTSW), – Initial module submission marks an important milestone in the pre-market approval process – – Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and feedback from the FDA as each module is submitted – – Module submitted in parallel to execution of ReSTART pivotal study (Recurrent SCC […]